论文部分内容阅读
糖尿病作为一种慢性病,其患病率随着肥胖、人口老龄化及生活方式的改变,呈逐渐增长的流行趋势,波及的范围可以与14世纪的“黑死病”相媲美。随着人们对糖尿病了解的不断加深,临床上出现了一批新型降糖药,包括胰高血糖素样肽-1(GLP-1)类似物、二肽基肽酶-4(DPPⅣ)抑制剂和胰岛素类似物。目前,GLP-1类似物和DPP-4抑制剂已经在临床上广泛使用,不过,其安全性和疗效还亟待进一步确定。下面就让我们对近年来新出现的糖尿病药物做一下总结。
Diabetes as a chronic disease, its prevalence with the obesity, the aging population and lifestyle changes, showing a growing trend of epidemics, spread to the extent of the 14th century “Black Death” comparable. With the deepening of people’s understanding of diabetes, clinically a number of new hypoglycemic drugs, including glucagon-like peptide-1 (GLP-1) analogues, dipeptidyl peptidase-4 (DPP IV) inhibitors And insulin analogues. Currently, GLP-1 analogs and DPP-4 inhibitors have been widely used clinically, however, their safety and efficacy still need to be further determined. Let’s take a look at the emerging diabetes drugs in recent years.